The hemophilia market is expected to experience significant growth due to advancements in gene therapy, innovative treatments, and an increasing focus on personalized medicine. Rising awareness and ...

Researchers have made a groundbreaking discovery in the field of hematology, providing an explanation for spontaneous and unusual blood-clotting that continues to occur despite treatment with ...

The government has set aside £11.8bn to compensate victims of the infected blood scandal, after a public inquiry found the ...

Novo Nordisk today announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia A with and without inhibitors. The trial initially assessed ...

Novo Nordisk’s haemophilia A therapy Mim8 stopped bleeding completely in 74.3% of children in a Phase III trial. The ...

Novo Nordisk has shared positive results from a late-stage study of its investigational haemophilia A therapy Mim8 in ...

Novo Nordisk today announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia A with and without inhibitors. The trial initially assessed ...

patients with autoimmune antibodies to factor VIII, and patients with bleeding associated with liver disease. These guidelines were developed by the hematology oncology service to identify the ...

Did you know that your blood type could play a much bigger role in your health than you thought? While cardiovascular risks are often associated with factors such as diet, smoking, and physical ...

while factor XIa activates it in the intrinsic coagulation pathway. Activated FIX, when combined with activated factor VIII, activates factor X. This leads to the transformation of prothrombin to ...